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Myeloidsarcoma(MS,previouslynamedgranulocyticsarcomaorchloroma)isarareextramedullarytumourofimmaturemyeloid
cells. It can be present before, concurrently with, or after the diagnosis of acute myeloid leukemia. MS is extremely uncommon
in acute promyelocytic leukemia (APL). In the case described here, MS was the sole site of APL relapse and the cause of spinal
cord compression. The patient presented with neurologic symptoms due to a paravertebral mass of MS after 7 years of complete
remission. He was treated with excision of the mass followed by local radiotherapy. Systemic treatment was also given with
combined arsenic trioxide and all-trans retinoic acid and the patient was able to achieve a second prolonged clinical and molecular
remission.
1.Introduction
Myeloid sarcoma (MS, previously named granulocytic sar-
coma or chloroma) is a rare extramedullary tumour of
immature myeloid cells [1]. It can occur in association
with myelogenous leukemia, myeloproliferative disorders,
and myelodysplasia. MS has diﬀerent modalities of presen-
tation and can aﬀect any organ. It may occur otherwise
in healthy individuals who subsequently develop an overt
typical myelogenous leukemia [1, 2]. MS can also develop
in leukemia patients concurrently with or after diagnosis,
or as a manifestation of disease relapse [3, 4]. The WHO
recognizes three major variants of MS based on the pre-
dominant cell type and the degree of maturation, namely
respectly, a myeloblast variant, with a mix of myeloblasts and
promyelocytes variant, and more diﬀerentiated variant with
promyelocytes and more mature granulocytes [5]. Acute
promyelocytic leukemia (APL) accounts for approximately
10% of acute myeloid leukemia (AML) and cases of MS
due to APL have been only occasionally reported [1–4]. We
report the case of a patient with APL who presented right
paraparesis after 7 years of complete remission. The patient
had a MS with paravertebral localization as the only site of
APL relapse.
2.CaseReport
In November 1999, a 38-year-old male presented with a
history of recurrent episodes of gum bleeding. Physical
examination was unremarkable, but a complete blood count
showed Hb 6.1g/dL, WBC 1 × 109/L, and platelets 2 ×
109/L. Microscopic examination of a blood smear showed
8% hypergranular promyelocytes, with Auer rods. At exam-
ination of bone marrow aspirate a diﬀuse inﬁltration by
atypical promyelocytes was apparent. The immunopheno-
type proﬁle of leukemic cells was consistent with APL
(CD33+ve, CD45+ve, HLA-DR-ve, CD34-ve, CD16-ve, and
CD56-ve). Cytogenetics revealed the characteristic t(15;17)
(q22;q21-q22) and the RT-PCR assay showed the typical
PML/RARα fusion gene thereby conﬁrming the diagnosis
of APL [6]. The patient was treated with all-trans retinoic2 Advances in Hematology
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Figure 1: (a) The pictures show adipose and ﬁbrous tissue with
dense and diﬀuse inﬁltrate of monomorphic PML cells (H
!E, 20×). (b) FISH revealed the presence of the reciprocal and
balanced t(15;17) on PML cells (arrow).
acid (ATRA) 45mg/m2/day ber 30 days and idarubicin
(IDA) 12mg/m2/day on days 2, 4, 6, and 8. On day
20, the patient had severe pulmonary distress that was
consistent with an ATRA syndrome [7]. This was success-
fully managed with high-dose dexamethasone and ATRA
discontinuation. Despite that, following induction, bone
marrow evaluation revealed a morphologic and molecular
picture of complete remission. The patient received 3
additional courses of chemotherapy as consolidation and
completed his treatment in July 2002. Five years later in
July 2007, the patient presented with right chest pain and
progressive right paraparesis in a few-week duration. An
MRI of the spine revealed a solid extramedullary intraspinal
mass extending between T6 and T8. Diagnostic workup
including coagulation proﬁle and complete blood counts
was normal, and neither atypical promyelocytes nor blast
cells were detected in peripheral blood and bone marrow. In
addition, PCR analysis for PML/RAR transcripted on bone
marrow cells conﬁrmed a status of molecular remission.
Cord decompression was performed with total laminectomy
and excision of an extradural soft tissue mass of 4cm ×
5cm × 5cm. Histopathology examination showed diﬀuse
inﬁltrationbymonomorphic,medium-sized,neoplasticcells
with round shaped deeply indented or bilobated nuclei with
dispersed chromatin, inconspicuous nucleoli, and basophilic
cytoplasm. The immunophenotype characteristics of neo-
plastic cells were as follows: myeloperoxidase and CD117
(c-KIT) were strongly positive; CD45 was weakly and
focally expressed while CD34, CD31, CD20, CD79a, CD3,
CD56, and CD15 were negative. Cytogenetic studies showed
(Figure 1) t(15;17) (q22;q21-q22) with PML/RARα fusion
gene as demonstrated by FISH LSI with PML/RARα probe
dual color (Dual fusion translocation probe, Vysis/Abbot).
Since the disease was localized to the spine, the patient
underwent a local radiotherapy with 36Gy.
Systemic therapy was also started on an outpatient basis
with combined ATRA and arsenic trioxide (ATO) for a total
of 5-month cycles according to the scheme reported by Estey
et al. [8]. The patient were able to achieve and maintain a
second complete hematologic remission. Currently, he is still
in remission and well 20 months since the end of treatment.
3. Discussion
Extramedullary disease (EMD) at diagnosis or at relapse
develops in 3%–8% of patients with acute myelogenous
leukemia, more frequently in those with myelomonocytic
and monocytic morphology [9–11] (M4 and M5 French-
American- British subtypes). Its occurrence in APL is
relatively rare but after the advent of ATRA it is increasingly
reported at time of relapse [11–29]. The case reported here,
is a rare case of CNS isolated relapse [13]. The patient
presented with neurologic symptoms due to a paravertebral
mass after 7 years of complete remission. He entered a
secondprolongedclinicalandmolecularremissionafterlocal
radiotherapy followed by a combination of ATRA and ATO.
This case represents the second report of MS resulting in
spinal cord compression due to APL extramedullary relapse.
The other case, reported by Tsimberidou et al. [30], was a
man who remained in complete remission for 3 years after
treatment of APL. This patient later developed paraplegia
due to a paravertebral mass at the level of T7-T8. Following
decompression laminectomy, an isolated extramedullary
promyelocytic relapse was diagnosed. The bone marrow was
not involved. The patient was treated with local radiotherapy
followed by ATRA and idarubicin, achieving a short second
remission. He subsequently developed a second relapse with
marrow and skin involvement.
T h eo c c u r r e n c eo fE M Dh a sl o n gb e e nc o n s i d e r e da
rare event in APL patients treated with chemotherapy alone,
whereas this phenomenon has increasingly been reported in
the ATRA era [5, 9, 38]. The question arises as to whether
treatment of APL with ATRA predisposes patients to the
development of EMD [38, 51]. This question is still open,
as various trials have shown contrasting results. Wiernik
et al. [3] suggested that extramedullary APL occurs more
frequently after ATRA than other therapies. Ko et al. [23]
demonstrated that patients receiving ATRA induction had
a 2.1 increased relative risk of EMD compared with those
with chemotherapy alone. In a literature review by Bae et
al. [51], only three of 21 cases with CNS relapse received
systemic chemotherapy without ATRA. Among 172 patients
with APL treated at MDACC between 1980 and 2003, a
total of three patients relapsed with isolated EMD and it
occurred exclusively in patients who had received ATRA-
containing induction regimens [51]. Ohno et al. [52]n o t e d
thatEMrelapsewasabsentfromall37patientswithrelapsing
APL in the Japanese chemotherapy only studies, while it
was seen in 8% of 121 patients in the chemotherapy plus
ATRA protocols and this raised the possibility that the
doses of chemotherapy given with ATRA-based regimens
are less intensive than those previously used and thus may
not reach therapeutic levels in the EM tissues. This could
be particularly relevant to protocols without cytarabine. A
relationship between EMD and ATRA treatment has been
suggested. Two possible explanations are considered. The
ﬁrst suggests a direct eﬀect of ATRA on adhesion molecules
resulting in increased inﬁltration capability of APL leukemia
blasts [23]. The second postulates the occurrence of MS in
relapsed patients as a consequence of the prolonged survival
[38]. In a study of the GIMEMA [38], the authors foundAdvances in Hematology 3
Table 1: Clinical features of patients with MS in APL.
References No. cases disease status Time since
Site of involvement
diagnosis/EMD relapse (months)
Fukushima et al. [31]1 o n s e t cerebellum + hematological
Worch et al. [32]1 o n s e t lytic lesions of humerus, tibia,
femur + molecular hematological
Ajarim et al. [33]1 o n s e t t h y m u s+h e m a t o l o g i c a l
Savranlar et al. [34]1 o n s e t thoracic-epidural
Brown et al. [35]1 o n s e t optic nerve + hematological
Agarwal et al. [36] 1 relapse 31 hip + hematological
Disel et al. [37]1 r e l a p s e9 pleura
Tsimberodou et al. [30] 1 relapse 36 thoracic spine
Specchia et al. [38] 1 relapse NA lung + hematological
3 relapse 155 mastoid + hematological
Latagliata et al. [39]7 1 mastoid + mol hematological
61 mastoid
3r e l a p s e 7
subcutaneous nodules at sternal
manubrium + wrist at level of the
radial artery pulse + site of
intravenous catheter scar+ mol
hematological
Sanz et al. [40]6
subcutaneous nodules at jugular
catheter scar + wrists at level of the
radial artery pulse + molecular
hematological
32 sternal manubrium + subcutaneous
nodule + antecubital fossa
Magliulo et al. [41] 1 relapse 24 external auditory canal+ mol
hematological
Nasilowska-Adamska et al. [42] 1 relapse 21 pleura, heart and pericardium
Slavecheva et al. [43] 1 relapse 120 lymph node
Kai et al. [44]1 r e l a p s e s N A 4 time at diﬀerent sites
Tobita et al. [45]1 r e l a p s e sN A 1st and 2nd external auditory canal
F o r r e s te ta l .[ 46] 1 relapse 1st 48-2nd 24 1st testicular -2nd retroperitoneal
nodes, psoas muscle and skin
Skarin et al. [47]1 r e l a p s e 8 CNS + hematologic
Leoni et al. [48] 2r e l a p s e N A
(1) central nervous system + middle
ear + lymph nodes.
(2) skin + lymph nodes
Ammatuna et al. [49] 1 relapse NA
1st and 2nd -scalp + mol
hematological 3rd mol
hematological + breast
Breccia et al. [50] 7r e l a p s e
5f r o mC R (1) left auricular canal + mastoid +
mol hematological
69 (2) left mastoid + mol
hematological
58 (3) left mastoid
9 (4) left mastoid + hematologic
12 (5) left mastoid + hematologic
64 (6) right auricular canal
6f r o m2 n dC R (7) right mastoid + CNS + mol
hematological
NA: not available; mol: molecular; CR: complete remission;4 Advances in Hematology
no statistical diﬀerence in the frequency of extramedullary
involvement between patients treated with or without ATRA.
EMD was documented in 5% and 12% of patients included
in the LAP0389 and AIDA protocol, respectively, with no
statistical diﬀerence. In particular, the ﬁve EMD localizations
in the LAP0389 study were in the CNS (1 patient), the skin
(3 patients), and the middle ear (1 patient). Of the 16 EMD
relapses in the AIDA study, 10 involved the CNS and six
involved other extramedullary sites (the skin in 3, the middle
earin2,andthelungin1).ThusCNSdiseaseatrelapseseems
frequent among the AIDA treated patients (8% versus 1%)
[39]. Breccia et al. [50] described three adult patients with
middle ear localizations at relapse. They had been previously
treated with ATRA and CT. Their characteristics are shown
in Table 1.
Similarly, C. Samanez et al. [53]r e p o rt e d7c a s e so fE M D
relapse in APL patients receiving chemotherapy (CT) alone
(102 patients) or combined with ATRA (155 patients). EMD
relapse rate was 4.4% in the CT group and 8.7% in the
group CT plus ATRA, with no statistical diﬀerences. EMD
localizations were in soft tissues (3 patients), the CNS (2
patients), the tonsils (1 patient), liver (1 patient), and the
testis (1 patient). De Botton et al. [54] analyzed EMD relapse
occurring in patients with APL treated with ATRA and CT.
Of 740 patients included in three multicenter trials (APL91,
APL93 trials, and PETHEMA 96) 10 patients developed
EMD relapse. Of these, 9 were in the CNS and one in
the skin. Only two patients had isolated EMD relapses. A
signiﬁcant correlation could be found between high WBC
count and the risk of CNS relapse. More recently, Casanova
et al. [55] reported a similar pattern of increased CNS EMD
relapse in APL patients treated with ATRA and CT. EMD
relapse was found in 8 of 74 (15%) APL patients (CNS:
5, external ear: 3). Together, these studies conﬁrm that the
CNS is the preferential site of extramedullary involvement
in APL, raising an issue of whether or not to consider CNS
prophylaxis in APL treatment protocols especially in patients
presentingwithhyperleukocytosis,assuggestedbytheexpert
panel of the European Leukemia Net. However, the beneﬁt
of this policy has not been established in prospective studies
[56].The occurrence of the ATRA syndrome was recognized
to be a signiﬁcant risk factor for EMD involvement at relapse
[57].SinceAPLcells,inpatientsaﬀectedbyATRAsyndrome,
inﬁltrate multiple tissues and organs, including the lung and
the skin, it was hypothesized that ATRA could promote the
migration of diﬀerentiating blasts into the skin, the CNS,
and other tissues which represented a reservoir of viable
blasts. These cells could later proliferate and result in an
E M Dr e c u r r e n c e[ 9, 11, 23, 27, 57]. Others have found
that elevated WBC count (>10 × 109 L) on presentation
[55], predominance of the PML/RARα bcr3 type, and
mirogranularmorphology[50]areconsideredasriskfactors.
Management of relapse in the CNS and other extramed-
ullary sites in patients with APL is a challenging issue for
which there is a notable lack of information. EMD relapse,
including in the CNS, can occur either in isolation or asso-
ciated with BM involvement as a ﬁrst relapse, and also after
oneormorehematologicrelapses.Optimalmanagementand
outcome of APL patients in these diﬀerent situations have
not been critically assessed. In case of granulocytic sarcoma,
wherever it is localized, radiation and intensive systemic
therapy might be considered.
Before the demonstration of the striking activity of ATO
in APL, salvage therapy usually consisted of the readmin-
istration of ATRA and chemotherapy for induction, gener-
ally containing high-dose cytarabine and an anthracycline,
followed by further chemotherapy and/or hematopoietic
stem cell transplantation (HSCT) [58–60]. Conﬁrmation of
the high and sustained eﬃcacy of ATO in patients with
relapsed/refractory APL has been provided by more recent
studies [61, 62]. CR rates in these trials were 80%–90%
and, in those studies that evaluated survival, 50%–70%
of patients were alive at 1 for 3 years. Current evidence
suggests that the use of at least 2 cycles of ATO results in
the achievement of second molecular CR in nearly 80% of
cases[63].ThebestconsolidationstrategyafterATOinduced
second remission is unknown; options include continued
treatment with repeated cycles of ATO, the use of standard
chemotherapy in combination with ATRA and/or ATO, and
HSCT. For patients unﬁt to proceed to HSCT, the available
options include repeated cycles of ATO with or without
ATRA/standard chemotherapy.
The central nervous system (CNS) is the commonest
site of extramedullary disease in APL and at least 10% of
hematologic relapses are accompanied by CNS involvement
[11]. Because the majority of CNS relapses occur in patients
presenting with hyperleukocytosis some strategies include
CNS prophylaxis for patients in this particular high-risk
setting. For such patients, it is advisable to postpone CNS
prophylaxis until after the achievement of CR because
lumbar puncture at presentation and during induction is
extremely hazardous. However, the beneﬁt of this policy has
notbeenestablished.Forpatientswithouthyperleukocytosis,
in whom the risk of CNS relapse is extremely low, there is a
general consensus to avoid CNS prophylaxis.
CNS prophylaxis for patients in this particular high-
risk setting. For such patients, it is advisable to postpone
CNS prophylaxis until after the achievement of CR because
lumbar puncture at presentation and during induction is
extremely hazardous. However, the beneﬁt of this policy has
notbeenestablished.Forpatientswithouthyperleukocytosis,
in whom the risk of CNS relapse is extremely low, there is a
general consensus to avoid CNS prophylaxis.
In conclusion, the increasing number and special pattern
of EMD involvement in relapsing APL patients emphasize its
importance in the diﬀerential diagnosis of EMD localization
in patients with history of APL. they also highlight the
need for understanding the underlying pathogenesis and
predisposing factors, as well as for selecting the optimal
treatment approach.
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